AAAM2020: Yoshitsugu Miyazaki - Challenge for chronic pulmonary aspergillosis

Описание к видео AAAM2020: Yoshitsugu Miyazaki - Challenge for chronic pulmonary aspergillosis

Long-term azole therapy is the mainstay of treating chronic pulmonary aspergillosis, but some patients harbour azole-resistant Aspergillus strains, which often carry CYP51A mutations. CRISPR-Cas9 genome editing was used to create strains with one or more mutations seen in clinical isolates to determine whether they were responsible for resistance, and then used molecular docking to show the mechanism.


Advances Against Aspergillosis and Mucormycosis 2020. 27-29th February

Комментарии

Информация по комментариям в разработке